The Enterprise Value as of December 2025 (TTM) for Gyre Therapeutics, Inc. (GYRE) is 659.37M

According to Gyre Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 659.37M. This represents a change of -9.63% compared to the average of 729.67M of the last 4 quarters.

Gyre Therapeutics, Inc. (GYRE) Historical Enterprise Value (quarterly & annually)

How has GYRE Enterprise Value performed in the past?

The mean historical Enterprise Value of Gyre Therapeutics, Inc. over the last ten years is 887.38M. The current 659.37M Enterprise Value has changed 7.33% with respect to the historical average. Over the past ten years (40 quarters), GYRE's Enterprise Value was at its highest in in the March 2018 quarter at 3.06B. The Enterprise Value was at its lowest in in the March 2017 quarter at 126.28M.

Gyre Therapeutics, Inc. (GYRE) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Gyre Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Gyre Therapeutics, Inc. (GYRE) Average Enterprise Value

How has GYRE Enterprise Value performed in the past?

The current Enterprise Value of Gyre Therapeutics, Inc. (GYRE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Gyre Therapeutics, Inc. (GYRE) Enterprise Value vs. Peers

How is GYRE’s Enterprise Value compared to its peers?

Gyre Therapeutics, Inc.’s Enterprise Value is greater than Anavex Life Sciences Corp. (258.01M), less than Erasca, Inc. (1.01B), less than CytomX Therapeutics, Inc. (681.92M), less than MBX Biosciences, Inc. Common Stock (780.59M), less than MoonLake Immunotherapeutics (711.84M), less than Astria Therapeutics, Inc. (665.98M), greater than Keros Therapeutics, Inc. (195.13M), less than MeiraGTx Holdings plc (704.81M), greater than Iovance Biotherapeutics, Inc. (650.41M), less than ArriVent BioPharma, Inc. Common Stock (895.37M),

Build a custom stock screener for Gyre Therapeutics, Inc. (GYRE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gyre Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Gyre Therapeutics, Inc. (GYRE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Gyre Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.